Key facts
- A meta-study compared tirzepatide, semaglutide, and liraglutide for weight loss.
- The study was conducted by the University of Georgia.
- The comparison focused on non-diabetic patients.
- Tirzepatide showed the most significant weight loss.
- Patients using tirzepatide lost over 20% of their starting weight on average.
A comprehensive meta-study conducted by the University of Georgia has evaluated the comparative effectiveness of three prominent GLP-1 receptor agonist drugs used for weight loss in non-diabetic individuals. The drugs examined were tirzepatide, semaglutide, and liraglutide. The findings indicate that tirzepatide demonstrated the most substantial impact on weight reduction among the studied medications. Patients treated with tirzepatide experienced an average weight loss of over 20% of their starting body weight. This level of efficacy surpassed that observed in patients using semaglutide and liraglutide, positioning tirzepatide as the leading option for significant weight loss in this non-diabetic population according to this analysis.